Abstract Number: 2318 • 2016 ACR/ARHP Annual Meeting
Real World Use of the Myositis Autoantibody Panel
Background/Purpose: The identification of myositis specific and associated autoantibodies occurring in idiopathic inflammatory myopathies (IIMs) has improved classification and prognosis determinations. With commercial availability, these…Abstract Number: 2658 • 2016 ACR/ARHP Annual Meeting
Adverse Drug Reactions Due to Disease Modifying Drugs in Patients with Rheumatoid Arthritis
Background/Purpose: There is a high risk of developing adverse drug reactions (ADR) in rheumatology due, mainly, to the Disease Modifying Drugs (DMARD) used. After more…Abstract Number: 2686 • 2016 ACR/ARHP Annual Meeting
Objective Improvement in Fatigue Scores for Primary Sjögren’s Patients Receiving a Tailored Multidisciplinary Fatigue Intervention in a Generic Fatigue Clinic
Background/Purpose: Primary Sjögren’s syndrome (PSS) is an autoimmune disease which targets secretary glands resulting in dry eyes and mouth. Approximately 70% of PSS patients experience…Abstract Number: 81 • 2016 ACR/ARHP Annual Meeting
Understanding the Importance of a Patient’s Role in the Management of RA: Physician- and Patient-Based Survey
Background/Purpose: RA is a chronic, debilitating condition for which there is no cure. To identify and better understand the perspectives of both healthcare providers (HCPs)…Abstract Number: 3138 • 2016 ACR/ARHP Annual Meeting
Sustained Improvement in Follow-up of Hypertension in Rheumatology Patients: Results of an Intervention Sustainability Assessment
Background/Purpose: Hypertension (HTN) is the most prevalent comorbid cardiovascular disease (CVD) risk factor among adults with rheumatic conditions. However, we previously found that high blood…Abstract Number: 90 • 2016 ACR/ARHP Annual Meeting
Impacts of Anti-TNF Treatment on Improvement in Work Place and Household Productivity in Patients with Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is a unique inflammatory arthritis that affects the skin, nails, and the joints. Most of the patients consider PsA to have…Abstract Number: 3150 • 2016 ACR/ARHP Annual Meeting
The Initial Dose of Methotrexate per Weight Is Determinant of Disease Activity and Early DAS28 Remission in DMARD-Naive Early Rheumatoid Arthritis Patients Receiving Usual Care
Background/Purpose: Methotrexate (MTX) is considered as the anchor disease modifying antirheumatic drug (DMARD) in treatment of rheumatoid arthritis (RA). However, there is no advice…Abstract Number: 267 • 2016 ACR/ARHP Annual Meeting
Diffuse Idiopathic Skeletal Hyperostosis: Can We Identify Different Clinicoradiological Patterns?
Background/Purpose: Diffuse Idiopathic Skeletal Hyperostosis (DISH) was described based on vertebral radiological signs (Resnick). Subsequently, Utsinger presented other criteria that add extraspinal involvement that allowed…Abstract Number: 3211 • 2016 ACR/ARHP Annual Meeting
Early Radiological Progression in Rheumatoid Arthritis Leads to More Long-Term Joint Damage in Daily Clinical Practice; Six Year Radiological Outcomes of a Strict Treat-to-Target Cohort in the Netherlands
Background/Purpose: Implementation of treat-to-target (T2T) in Rheumatoid Arthritis (RA) leads to limited radiological damage during follow-up of 3 years. Questions are whether these results are…Abstract Number: 547 • 2016 ACR/ARHP Annual Meeting
Concordance Between Ultrasound Joint Synovitis and Clinical Joint Assessments By Patients or Physicians in Rheumatoid Arthritis
Background/Purpose: Ultrasonography (US) has been prevalently used as a valid and objective modality for joint examination in patients with rheumatoid arthritis (RA). This study aimed…Abstract Number: 592 • 2016 ACR/ARHP Annual Meeting
Impact of Adherence to Tumor Necrosis Factor Inhibitors on Radiographic Outcomes in US Veterans with Rheumatoid Arthritis
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are effective therapy for rheumatoid arthritis (RA) and have been shown to reduce progression of joint structural damage…Abstract Number: 705 • 2016 ACR/ARHP Annual Meeting
Is a Positive Family History of Spondyloarthritis of Value in Patients with Chronic Back Pain? Results from Two Large Early Back Pain Cohorts
Background/Purpose: To assess whether presence of spondyloarthritis (SpA) manifestations in first- and second-degree relatives of patients with chronic back pain (CBP) is associated with higher…Abstract Number: 729 • 2016 ACR/ARHP Annual Meeting
Does the Presence of Multiple Spondyloarthritis-Features in Patients with Chronic Back Pain Always Lead to Diagnosis of Axial Spondyloarthritis?
Background/Purpose: The number of clinical spondyloarthritis (SpA)-features plays an important role in the Assessment of SpondyloArthritis international Society (ASAS) modified Berlin algorithm for the diagnostic…Abstract Number: 906 • 2016 ACR/ARHP Annual Meeting
Treatment with Methotrexate and Risk of Relapses in Patients with Giant Cell Arteritis in Clinical Practice
Background/Purpose: Several Clinical trials indicate that Methotrexate (MTX) could be considered as a feasible option in addition to corticosteroids for patients with GCA, but there…Abstract Number: 2107 • 2015 ACR/ARHP Annual Meeting
Initiation of Combination Triple Therapy in Real World Clinical Practice Rarely Replicates the Protocols Used in Randomized Controlled Trials.
Background/Purpose: Combination therapy with methotrexate (MTX), sulfasalazine (SUL), and hydroxychloroquine (HCQ) [triple therapy] is an effective treatment for rheumatoid arthritis (RA). Randomized controlled trials…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- Next Page »